oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Oral semaglutide for the treatment

Alpers, G.L

The liver filters out waste and toxins that build up in the body due to daily exposure to impurities and toxins

Enhanced release of glucose into the intraluminal space of the intestine associated with metformin treatment as revealed by [18F]fluorodeoxyglucose PET-MRI

Although no study has directly compared the effects of repaglinide and mitiglinide, significant reductions in HbA1c and fasting plasma glucose were observed in a report of patients who switched from mitiglinide (30 mg/day) to repaglinide (1.5 mg/day) [15], and it was presumed that the hypoglycemic effect of repaglinide (1.5 mg/day) was stronger than that of mitiglinide (30 mg/day)